← Insider Monitor
Boundless Bio, Inc. logo
BOLD

Boundless Bio, Inc.

Nasdaq · Pharmaceutical Preparations

4
Insider trades
0
Congress trades

Company Overview

A concise company profile alongside the latest public filing activity.

Boundless Bio is a biopharmaceutical company developing therapies targeting extrachromosomal DNA (ecDNA)-driven cancers, a mechanism of tumor cell gene amplification linked to aggressive disease and treatment resistance. The company's lead programs are designed to selectively target cells harboring ecDNA to treat cancers that are difficult to address with existing therapies.

Industry
Pharmaceutical Preparations
Headquarters
La Jolla, CA
Exchange
Nasdaq

Company profile sourced from SEC filings.

Corporate Insider Trades

Open-market purchases and sales by directors, officers, and other company insiders.

InsiderTypeValueDate
TANG KEVIN10% OwnerBuy$277KOct 16, 2026
TANG KEVIN10% OwnerBuy$30KOct 19, 2026
TANG KEVIN10% OwnerBuy$43KOct 19, 2026
TANG KEVIN10% OwnerBuy$521Oct 20, 2026

Source: SEC EDGAR Form 4 filings

Congressional Trades

Recent disclosures by members of the U.S. House and Senate.

No recent congressional disclosures found for BOLD.

Source: Senate eFD and House Clerk STOCK Act disclosures

Get notable BOLD activity by email

Free alerts for the insider and congressional trades worth watching.

SMS is optional: we only save your number if you check the consent box and provide a valid number. US mobile numbers only.

SMS Terms and Privacy Policy.

By submitting your email address, you will receive a free subscription to the MySmarTrend e-letter, and offers from us and our affiliates that we think might interest you. You can unsubscribe at any time. Privacy Policy.

For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.